A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia

This Phase I study tests a three-drug combination — ziftomenib (a menin inhibitor), venetoclax, and gemtuzumab ozogamicin — in children and young adults with a type of blood cancer called acute myeloid leukemia (AML) that has returned or is not responding to standard treatments. **You may be eligible if...** - You are between 3 and 21 years old - You have relapsed or refractory AML (or a mixed-lineage leukemia with myeloid features) - Your leukemia has a specific genetic mutation (such as KMT2A rearrangement, NUP98, NPM1, or other HOX pathway mutations) - Your white blood cell count is below 25,000/µL at enrollment **You may NOT be eligible if...** - You have had a prior bone marrow transplant within a certain timeframe - Your overall health condition is too poor to tolerate the treatment Talk to your doctor to see if this trial is right for you.